Live respiratory syncytial virus vaccine D46/cp/ΔM2-2 is overattenuated in RSV-seronegative children
Clicks: 5
ID: 322757
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
1.2
/100
5 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #71 of 208 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract The intranasal respiratory syncytial virus (RSV) vaccine D46/cp/ΔM2-2 is attenuated by deletion of the RSV RNA synthesis factor M2-2 and 5 cold-passage amino acid mutations. D46/cp/ΔM2-2 was safe but over-attenuated in 12 to 59-month-old RSV-seropositive children (dose: 106 plaque-forming units [PFU]) and 6 to 24-month-old RSV-seronegative children (dose: 105 PFU).
| Reference Key |
openalex_W7171689376
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ruth A. Karron, Suzanne Woods, Kimberli Wanionek, Jennifer Oliva, Lijuan Yang, Cindy Luongo, Peter L. Collins, Ursula J. Buchholz |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag388
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.